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ABSTRACT
Background:  Insulin therapy has been the mainstay in managing women with gestational
diabetes mellitus (GDM), but some disadvantages of insulin have led to the use of glyburide,
which is inexpensive in some countries, to manage GDM. However, there has been debate
over its effectiveness, efficacy and safety when compared to insulin for maternal glycaemic
control, and some adverse neonatal outcomes in GDM.
Method:  A  systematic  review  of  eight  randomised  controlled  trial  (RCT)  studies  was
undertaken  to  compare  glyburide  and  insulin.  Studies  involving  849  participants  were
included in the quantitative analysis. 
Results:  There  was  no  significant  difference  between  glyburide  and  insulin in  maternal
fasting (P= 0.09; SMD: 0.13; 95% CI: -0.02 to 0.28) and postprandial (P= 0.45; SMD: 0.05;
95% CI: -0.09 to 0.19) glycaemic control and glycosylated haemoglobin (P= 0.35; SMD:
0.08; 95% CI: -0.08 to 0.24). When compared with insulin, glyburide had an increase risk
ratio (RR) for neonatal hypoglycaemia (P= 0.0002; RR: 2.27; 95% CI: 1.47 to 3.51) and large
for gestational age babies (P= 0.03; RR: 1.60; 95%CI: 1.06 to 2.41). Estimation of standard
mean  difference  shows  that  neonatal  birth  weight  was  significantly  higher  in  subjects
receiving glyburide than in the insulin group (P= 0.002; SMD: 0.21; 95% CI: 0.08 to 0.35).
Conclusions: Glyburide was seen to be clinically effective and a safer alternative to insulin
for maternal glycaemic control in GDM women. It is affordable, convenient and requires no
comprehensive educative training at the time of initiation of therapy. However, its adverse
outcomes – neonatal hypoglycaemia, high neonatal birth weight and large for gestational age
babies – call for careful monitoring of GDM patients for any need for supplemental insulin.
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1. Introduction
Globally, gestational diabetes mellitus (GDM) is associated with about 14% of complicated
pregnancy  cases  per  annum.  Amongst  the  common  complications  are  macrosomia,
haemorrhage,  hypertensive  disorder,  stillbirth  and  type  2  diabetes  mellitus  (T2DM).  The
World  Health  Organisation  (WHO) prioritised  improvement  in  maternal  health,  including
management of GDM, as one of its Millennium Development Goals (MDG) [1, 2]. However,
the rapid rise in the incidence of GDM reduces the likelihood of attaining this goal [3]. 
There is a wide range of therapeutic measures to control GDM, including dietary changes and
physical activities either alone or in combination, but insulin therapy remains the technique of
choice after diet and physical exercise [4-6]. A majority of women who use diet and physical
activities incorporate either insulin or oral hypoglycaemic agents in their treatment plan [4, 5].
However, the disadvantages of insulin use – such as multiple daily injection sites, maternal
weight  gain,  risk  of  hypoglycaemia,  cost  of  drugs,  handling  and  storage,  and  the
modifications to drug administration based on body mass index, glucose level and lifestyle [6]
– have led to the consideration of sulfonylurea (oral hypoglycaemic agents) as a preferred
alternative [6]. 
The formerly traditional use of sulfonylurea drugs in pregnancy has now been discouraged
due to the risks of fetal teratogenicity and neonatal hypoglycaemia as a result of its 10-16%
maternal-to-fetal transfer rate [4, 5]. By contrast, glyburide has been found to have low risk of
infant growth and teratogenicity, minimal in vitro foetal transfer rate, and safer in vivo fetal-
to-maternal transfer rate at a dose of up to 20mg per day [4]. Furthermore, it is an inexpensive
oral medication compared to insulin [7] and requires no special storage condition nor special
training to administer.
There have been several RCTs that compared glyburide and insulin in the management of
GDM.  However,  most  lack  statistical  power.  Therefore,  this  systematic  review  aims  to
provide a  pooled estimate  of RCTs comparing  the relative  effectiveness  of glyburide and
insulin on maternal glycaemic control and neonatal outcomes.
2. Methods
2.1 Search Strategy
We performed a systematic review and meta-analysis in accordance with the standards set by
the Preferred Reporting Items for Systematic Review and Meta-analysis (PRISM) checklist
(figure  1).  We  carried  out  an  extensive  electronic  database  search  of  published  and
unpublished  RCTs  comparing  glyburide  and  insulin  in  the  management  of  GDM.  We
searched  Cochrane  Library  (Issue  6,  2014),  PubMed,  CINAHL  Plus  with  Full  Text,
MEDLINE, BioMed Central,  Health Technology Assessment  (HTA), and Latin American
and Caribbean Health Sciences (LILIACS) between the years 2000 and 2014. We use the key
words “glyburide” AND “insulin” AND “management of gestational diabetes mellitus”, and
also “Glyburide” AND “GDM”. We also hand-searched references of retrieved articles  to
identify studies not captured by our primary search strategy. 
2.2 Study Selection
Figure 1 illustrates  how the PRISM checklist  was used to document the process of study
selection  [8].  We  included  randomised  controlled  trial  studies  comparing  GDM  patients
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treated with glyburide versus GDM patients treated with insulin. The inclusion criteria were:
a) participants were patients with GDM irrespective of their age, gravidity and parity, b) study
design  was  RCT,  c)  intervention  entails  studies  that  compare  glyburide  and  insulin
medication, and d) outcome entails studies that measure one or more of these endpoints: 1)
maternal fasting plasma glucose (FBS), 2) 2-hours postprandial plasma glucose (OGTT), 3)
maternal glycosylated haemoglobin (HbAIC), 4) neonatal hypoglycaemia (NH), and 5) large-
for-gestational  age  baby (LGA) and birth  weight  at  delivery  (BW).  Case  control  studies,
observational studies, retrospective studies, and women with pre-gestational diabetes and type
2 diabetes were excluded.
2.3 Data Extraction and Quality Assessment
Data were extracted in duplicate by two independent reviewers (J.O. and M.A.M.) [9]. Table
1 shows the data that were abstracted regarding the baseline characteristics of the included
studies [9]. These included: year of publication, study design, country of study, study size,
comparison patient characteristics, glyburide group requiring insulin, dose of glyburide, dose
of insulin, duration of study, and loss to follow up.
Data were extracted and appraised in accordance to the methodological  quality,  outcomes
measures and predetermined criteria relevant to the research questions. Figure 2 illustrates
how the characteristics for quality appraisal such as random sequence generation, blinding
treatment for subjects and personnel, outcome assessments, completeness of outcomes data,
objective  reporting  and  risks  of  potential  bias  were  evaluated  using  Review  Manager
(Revman) Version 5.1 (CDSR) [10], high risk of selection bias was detected in one of the
studies  [6]  this  was  taken  into  consideration  in  analysis  and  interpretation  of  findings.
Furthermore, for such a small study it was concluded that including it will not influence the
overall outcome of the study.
2.4 Statistical Analysis
All data analyses were performed using Review Manager 5.1 (Nordic Cochrane Centre). The
quantitative analyses were performed using the fixed effect model. For continuous outcomes,
standardised mean differences (SMD) and 95% confidence intervals (CI) were calculated. For
the dichotomous outcomes, risk ratio (RR) and 95% CI were calculated.
The  heterogeneity  was  estimated  statistically  by  the  Chi-squared  test  (P  >  0.1, which
suggested a lack of heterogeneity for continuous variables) and I-squared test value (I2 > 75%
was regarded as great heterogeneity).  In addition,  homogeneity of studies was graphically
assessed using visual interpretation of forest plots.
3.0 Results
As represented  in  figure  1,  a  total  of  185 potential  articles  were screened.  Eight  articles
fulfilled  all  the  inclusion  criteria  and  were  included  in  the  systematic  review.  The
characteristics and quality assessments of the studies are presented in tables 1 and 2. Overall
quality  and each study assessment are represented in figure 2. Both glyburide and insulin
subjects  were  matched  for  age,  body  mass  index,  gestational  weeks,  fasting  and  2-hour
postprandial blood glucose, and glycosylated haemoglobin level at the time of entry to the
study.
A total of 849 subjects were included in these eight studies (418 on glyburide and 431 on
insulin) as presented in table 3. 
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Figure 1: Search strategy for randomised controlled trials included in this study  
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Table 1: Characteristics and quality assessment of included studies
First author (year of 
publication)
Study design Country of 
study
Study size/comparison Patient 
characteristics
Glyburide 
group 
requiring 
insulin     
(n)
Dose of glyburide Dose of insulin Duration of
study
Loss to follow 
upGlyburide  
(n)
Insulin 
(n)
Langer et al. 2000 [1] Randomised 
controlled trials
Texas, United 
States
201 203 404 GDM 
women between
18 and 40 years 
old
8 9 ± 6mg/day 85 ± 48 units/day Not stated undeclared
Bertini et al. 2005 [2] Randomised 
controlled trials
Joinville SC, 
Brazil
24 27 70 GDM 
women
5 5-20mg/day 0.7-0.9 units/kg 9 months undeclared
Anjalakshi et al. 2006
[3]
Randomised 
controlled trials
Chennai, India 10 13 26 GDM 
women 
0 0.625mg and dose 
titrated once a week
0.1units/kg and 
increased weekly
Not stated Greater than 
10%
Silva et al. 2007 [4] Randomised 
controlled trials
Joinville SC, 
Brazil
32 36 68 GDM 
women, 
minimum 18 
years old
6 5-20mg/day 0.7-0.9 units/kg 1 year and 5
months
Not significant
Ogunyemi et al. 2007
[5] 
Randomised 
controlled trials
Los Angeles, 
United States
48 49 97 GDM 
women
3 5 mg 60 units 3 years Less than 10%
Lain et al. 2009 [6] Randomised 
controlled trials
Pittsburgh, 
United States
41 41 99 GDM 
women
1 8 ± 6.7mg/day 51.3 ± 33.4 units/
day
3 years Greater than 
10%
Mukhopadhyay et al. 
2012 [7]
Randomised 
controlled trials
Kolkata, India 30 30 60 GDM 
women
0 2.5 mg and increased 
weekly to a maximum
dose of 20mg/day
0.7 units/kg three 
times a day and 
increased when 
necessary
1 year undeclared
Anjali et al. 2013 [8] Randomised 
controlled trials
New Delhi, 
India
32 32 64 GDM 
women
2 5 ± 1.9mg/day to a 
maximum dose of 
20mg/day
33.8 ± 22.9 units/
day to a 
maximum dose of
84 units /day
1 year Less than 10%
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Figure 2: Summary of systematic review authors’ judgement on methodological quality
of included studies 
         
3.1 Maternal Glycaemic Control
The data on fasting blood glucose were reported in five studies (Figure 3.1a). The average
blood  glucose  was  slightly  lower  in  the  insulin  group than  the  glyburide  group,  but  the
difference was not statistically significant (P= 0.09; SMD: 0.13; 95% CI: -0.02 to 0.28) and
the 95% confidence interval crosses the line of no effect. 
7
Figure 3.1(a): Data on fasting blood glucose in insulin group compared with the glyburide group
The mean postprandial blood glucose was reported in seven studies (Figure 3.1b). There was
no significant difference in postprandial glycaemic control between glyburide and insulin (P=
0.45;  SMD: 0.05;  95% CI:  -0.09 to  0.19),  although the  overall  estimated  effects  slightly
favours insulin groups compared to glyburide with the 95% confidence interval crossing the
line of no effect.
Figure 3.1(b): Mean postprandial blood glucose between glyburide and insulin 
Glycosylated haemoglobin control was reported in four studies (Figure 3.1c) and no statistical
difference was observed between the two treatment groups (P= 0.35; SMD: 0.08; 95% CI: -
0.08 to 0.24), although again the overall estimated effects slightly favours insulin and the 95%
confidence interval crosses the line of no effect.
Figure 3.1(c): Glycosylated haemoglobin control
3.2 Neonatal Outcomes
Neonatal birth weight was reported in eight studies (Figure 3.2a). There was a significant
difference in the neonatal birth weight between glyburide and insulin groups (P= 0.002; SMD:
0.21; 95% CI: 0.08 to 0.35). The overall estimated effects favours insulin, indicating neonatal
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birth  weight  was  significantly  higher  in  patients  receiving  glyburide  than  those  receiving
insulin. The 95% confidence interval does not cross the line of no effect.
Figure 3.2(a): Neonatal birth weight between glyburide and insulin groups
Neonatal hypoglycaemia was observed in seven studies, defined as when the mean neonatal
blood glucose value  was less  than  40mg/dl  (Figure 3.2b).  Incidence  of  cases  of  neonatal
hypoglycaemia was significantly  greater  among neonates  born from GDM women treated
with glyburide than those treated with insulin. There was a statistically significant difference
between the two treatments groups (P= 0.0002; RR: 2.27; 95% CI: 1.47 to 3.51), and the 95%
confidence interval does not cross the line of no effect.
Figure 3.2(b): Neonatal hypoglycaemia among neonates born from GDM women treated with 
glyburide compared to insulin groups
Neonatal birth weight at or above the 90th percentile was considered large for gestational age
and was reported in five studies (Figure 3.2c). There was a significant difference between the
two groups treated with glyburide and insulin (P= 0.03; RR: 1.60; 95%CI: 1.06 to 2.41), with
incidence of large for gestational  age babies significantly higher in glyburide groups. The
95% confidence interval does not cross the line of no effect.
Figure 3.2(c): Incidence of large for gestational age babies in glyburide groups compared to insulin groups
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Outcome Included 
studies
Included 
participants
Heterogeneity 
Chi-squared 
(p)
I-Squared 
(%)
95% CI P
Maternal fasting 
plasma glucose 
control
5 711 3.27 (p=0.51) 0.0 SMD 0.13 (-0.02 to 
0.28)
0.09
Maternal 
postprandial 
plasma glucose 
control
7 798 14.41 (p=0.03) 58 SMD 0.05 (-0.09 to 
0.19)
0.45
Glycosylated 
haemoglobin 
control
4 584 5.51 (p= 0.14) 46 SMD 0.08 (-0.08 to 
0.24)
0.35
Neonatal birth 
weight
8 849 6.84 (p=0.45) 0.0 SMD 0.21 (0.08 to 
0.35)
0.002
Neonatal 
hypoglycaemia
7 829 6.88 (p=0.33) 13 RR 2.27 (1.47 to 3.51) 0.0002
Large for 
gestational age
5 661 9.99 (p= 0.04) 60 RR 1.60 (1.06 to 2.41) 0.03
Table 2: Summary of systematic review analysis results
Chi-squared test value p > 0.1 suggested a lack of heterogeneity for continuous variables.
I-squared test value I2 > 75% was regarded as great heterogeneity.
4.0 Discussion
Eight RCT studies were included in the systematic review, aiming at comparing glyburide and
insulin for the management of GDM (figure 3.1 a, b and c). The results showed a P value of
(P= 0.09;  SMD: 0.13;  95% CI:  -0.02  to  0.28  in  maternal  fasting  blood glucose,  2-hours
postprandial glucose level and glycosylated haemoglobin level, which could be interpreted as
no strong evidence that the intervention has an effect. However, it has be noted that this study
presented two P values one represented summary effect is from Z test and the other from χ2
related to the degree of heterogeneity.  In both cases P values in this study, they have been
greater than arbitrary P ≥ 0.05. This could be attributed to the fact that most of the studies
included in this review were small. It has been established that in small meta-analysis greater
P values are common, however, this should not be taken to imply that an intervention has no
important benefits.
Figures 3.1a indicates SMD = 0.13 in favour of glyburide over insulin in the control of blood
glucose. These findings compare favourably with previous studies that compared glyburide
and insulin therapy in management of GDM [4, 5]. Langer, Conway, Berkus et al. [5] went
further, explaining that glyburide reduces hyperglycaemia by increasing peripheral glucose
utilisation, decreasing hepatic gluconeogenesis and increasing insulin sensitivity through an
increase  in  intracellular  calcium  in  the  beta  cell  and  concurrently  stimulating  insulin
productivity [5]. 
The analysis  revealed that  there was a direct relationship between postprandial  glycaemic
level and pregnancy outcomes (figure 3.2 a, b and c) [11-16]. Consistent with previous studies
which showed that glyburide was effective on postprandial glycaemic control [17, 18]; seven
studies [11-16] showed no significant  difference between patients treated with insulin and
those treated with glyburide [figure 3.2 a, b and c].
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With regard to neonatal birth weight, this study showed significant difference between the
two groups treated with glyburide and insulin (P= 0.03; RR: 1.60; 95%CI: 1.06 to 2.41), with
incidence of large for gestational age babies significantly higher in glyburide groups (figure
3.2c). These findings were inconsistent with the previous observational study conducted by
Chmait, Dinise and Moore [19] which showed no statistical differences between these two
treatment groups [19]. 
Furthermore, this study showed a positive RR = 1.6 [fig 3.2c] of large for gestation age babies
among GDM women treated with glyburide compared to those treated with insulin. These
findings can be compared with a retrospective cohort study conducted by Cheng et al. [20]
which also indicated a greater likelihood of higher birth weight of infants above 4000g for
GDM mothers treated with glyburide compared to insulin treatments.
While glyburide appears to be a promising alternative to insulin in treating GDM, there have
been several prominent side effects associated with it. Several studies [4, 20] found that there
is a 2.27 times greater likelihood of neonatal hypoglycaemia in mothers treated with glyburide
compare  to  insulin  treatments.  In  addition  there  are  other  reported  side  effects  such  as
respiratory  distress,  jaundice,  skin allergy,  anaphylactic  reactions,  elevated  liver  enzymes,
haematological disorder and low visual acuity due to imbalanced glycaemic level [20]. The
retrospective  cohort  study conducted  by Cheng et  al.  [20]  revealed that  neonates  born to
mothers treated with glyburide have a greater propensity to be admitted to NICU compared to
those managed using insulin. 
5.0 Conclusion
In summary, glyburide is clinically as effective as insulin when used alone in the management
of GDM, and provides a best efficacy and safety option when supplemented with insulin for
those patients unresponsive to glyburide. 
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